Want to join the conversation?
Gregg Gilbert with Deutsche Bank asks about REMICADE dynamics and the rate of erosion. $MRK said that on REMICADE, its strategy has been to try to hold on to as many existing patients that were currently treated. The company has done a good job with that. Most loss of revenue came from reference pricing due to lower prices from the biosimilars.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.